

Technology Appraisal Committee Meeting (Committee B)

Minutes: Confirmed

Date and Time: Tuesday 14 April, 10.00am to 5.30pm

Venue:
Prospero House
241 Borough High Street
London
SE1 1GA

| | | |
|-----------------|------------------------------------|----------------------------|
| Present: | 1. Chair, Dr. Amanda Adler | Present for all notes |
| | 2. Vice Chair, Professor Ken Stein | Present for all notes |
| | 3. Dr Ray Armstrong | Present for all notes |
| | 4. Dr. Jeff Aronson | Present for all notes |
| | 5. Professor John Cairns | Present for notes 1 to 28 |
| | 6. Matthew Campbell-Hill | Present for all notes |
| | 7. Mark Chapman | Present for all notes |
| | 8. Professor Daniel Hochhauser | Present for all notes |
| | 9. Mrs. Anne Joshua | Present for all notes |
| | 10. Dr. Sanjay Kinra | Present for all notes |
| | 11. Dr. Miriam McCarthy | Present for all notes |
| | 12. Professor Ruairidh Milne | Present for all notes |
| | 13. Mr. Christopher O'Regan | Present for notes 18 to 31 |
| | 14. Dr. Sanjeev Patel | Present for all notes |
| | 15. Professor John Pounsford | Present for all notes |
| | 16. Dr. Danielle Preedy | Present for all notes |
| | 17. Dr. Marta Soares | Present for all notes |
| | 18. Dr Nicky Welton | Present for all notes |

In attendance:

| | | |
|---------------------|--|-----------------------|
| Meindert Boysen | Programme Director, National Institute for Health and Care Excellence | Present for all notes |
| Dr Elisabeth George | Associate Director, National Institute for Health and Care Excellence | Present for all notes |
| Jeremy Powell | Project Manager, National Institute for Health and Care Excellence | Present for all notes |
| Stuart Wood | Administrator, National Institute for Health and Care Excellence | Present for all notes |

| | | |
|--|---|----------------------------|
| Sophie Laurenson | Technical Analyst, National Institute for Health and Care Excellence | Present for notes 1 to 18 |
| Raisa Sidhu | Technical Adviser, National Institute for Health and Clinical Excellence | Present for notes 1 to 18 |
| Chris Chesters | Technical Analyst, National Institute for Health and Care Excellence | Present for notes 19 to 31 |
| Eleanor Donegan | Technical Adviser, National Institute for Health and Clinical Excellence | Present for notes 19 to 31 |
| Sebastien Hinde, Centre for Health Economics | Research Fellow | Present for notes 19 to 27 |
| Dr Eldon Spackman, Centre for Health Economics | Health Economist | Present for notes 19 to 27 |
| Ros Wade, Centre for Reviews and Dissemination | Research Fellow | Present for notes 19 to 27 |
| Professor Anthony Bewley | Consultant Dermatologist nominated by Celgene | Present for notes 1 to 15 |
| Mr David Chandler | Chief Executive of PAPAA nominated by Psoriasis and Psoriatic Arthritis Alliance | Present for notes 1 to 15 |
| Professor Catherine Smith | Clinical Nurse Specialist nominated by British Dermatological Nursing Group | Present for notes 1 to 15 |
| Professor Norman Waugh | Professor of Public Health | Present for notes 19 to 27 |
| Joshua Pink | Assistant Professor in Health Economics | Present for notes 19 to 27 |
| Professor Tim Spalding (clinical advisor to Warwick) | Orthopaedic Surgeon, University of Coventry and Warwickshire NHS Trust | Present for notes 19 to 27 |
| Professor Martyn Snow | Consultant Orthopaedic Surgeon nominated by Sobi | Present for notes 19 to 27 |

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of apremilast for treating moderate to severe plaque psoriasis and autologous chondrocyte implantation for repairing symptomatic articular cartilage defects of the knee (including a review of TA89)
2. The Chair informed the Committee of the non-public observers at this meeting: Dr Baxi, Specialty Registrar in Public Health.
3. Apologies were received from Professor Imran Chaudhry, Dr Rebecca Kearney, Dr Neil Iosson, Professor Stephen Palmer and Alun Roebuck

Any other Business

4. The Chair gave the Committee an update on the progress and timelines for other appraisals seen by the Committee.

Notes from the last meeting

5. Minutes from the 14 April committee meeting were approved

Appraisal of Apremilast for treating moderate to severe plaque psoriasis

Part 1 – Open session

6. The Chair welcomed the invited experts and Evidence Review Group representatives Professor Anthony Bewley, David Chandler, Professor Catherine Smith, Sebastien Hinde, Dr Eldon Spackman and Ros Wade to the meeting and they introduced themselves to the Committee.
7. The Chair welcomed company representatives from Celgene to the meeting.
8. The Chair asked all Committee members to declare any relevant interests
 - 8.1. Dr Amanda Adler, Professor Ken Stein, Dr Ray Armstrong, Dr Jeff Aronson, Professor John Cairns, Mr Matthew Campbell-Hill, Mr Mark Chapman, Professor Daniel Hochhauser, Mrs Anne Joshua, Dr Sanjay Kinra, Dr Miriam McCarthy, Professor Ruairidh Milne, Mr Christopher O'Regan, Dr Sanjeev Patel, Professor John Pounsford, Dr Danielle Preedy, Alun Roebuck, Marta Soares and Dr Nicky Welton all declared that they knew of no personal specific pecuniary interest, personal non-specific pecuniary interest, non-personal specific pecuniary interest, non-personal non-specific pecuniary interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of apremilast for treating moderate to severe plaque psoriasis.
 - 8.2. Chris O'Regan declared a non-personal specific pecuniary interest as his employer Merck, Sharp and Dohme UK Ltd is listed as a consultee on this appraisal

- 8.2.1. It was agreed that this declaration would prevent Chris O'Regan from participating in this part of the meeting.
9. The Chair asked all NICE Staff to declare any relevant interests.
 - 9.1. All declared that they knew of no personal specific pecuniary interest, personal non-specific pecuniary interest, non-personal specific pecuniary interest, non-personal non-specific pecuniary interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of apremilast for treating moderate to severe plaque psoriasis.
10. The Chair asked all other invited guests assessment group and invited experts, not including observers) to declare their relevant interests.
 - 10.1. All declared that they knew of no personal specific pecuniary interest, personal non-specific pecuniary interest, non-personal specific pecuniary interest, non-personal non-specific pecuniary interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of apremilast for treating moderate to severe plaque psoriasis.
 - 10.2. Professor Catherine Smith declared a personal non specific pecuniary interest as she is the principal investigator in the ongoing secukinumab trial.
 - 10.2.1. It was agreed that this declaration would not prevent Professor Catherine Smith from participating in this section of the meeting
 - 10.3. Professor Anthony Bewley declared a personal non specific pecuniary interest as he is a principal investigator on various studies within the UK and is involved in research on a range of biologics.
 - 10.3.1. It was agreed that this declaration would not prevent Professor Anthony Brewley from participating in this section of the meeting
11. The Chair introduced the lead team, Dr John Pounsford, Dr Danielle Preedy and Dr Marta Soares who gave presentations on the clinical effectiveness and cost effectiveness of apremilast for treating moderate to severe plaque psoriasis.
12. The Committee then discussed the clinical effectiveness, patient perspective and cost effectiveness of apremilast for treating moderate to severe plaque psoriasis on the basis of the evidence before them, and potential equality issues raised in this appraisal. They sought clarification and advice from the experts present. The discussions included:
 - 12.1. The experience of people with psoriasis and the assessment of disease severity.
 - 12.2. The current management of psoriasis and the potential positioning of apremilast in the treatment pathway.
 - 12.3. Whether the apremilast clinical trials were generalisable to UK clinical practice.
 - 12.4. The results of the company's network meta-analysis and the likely long-term effectiveness of apremilast.
 - 12.5. The company's modelling assumptions about utility values, hospitalisation rates and efficacy associated with best supportive care, frequency of physician visits and treatment wastage with apremilast.

- 12.6. The cost effectiveness estimates presented by the company, and exploratory analyses presented by the ERG.
13. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
14. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
15. The Chair then thanked the experts, company representatives and academic group for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

16. The Committee continued to discuss the clinical and cost effectiveness of apremilast for treating moderate to severe plaque psoriasis.
17. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of autologous chondrocyte implantation for repairing symptomatic articular cartilage defects of the knee (including a review of TA89)

Part 1 – Open session

18. The Chair welcomed the invited experts and Assessment Group representatives Professor Martyn Snow, Joshua Pink, Professor Norman Waugh and Professor Tim Spalding to the meeting and they introduced themselves to the Committee.
19. The Chair welcomed company representatives from Vericel, Sobi and Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust to the meeting.
20. The Chair asked all Committee members to declare any relevant interests
 - 20.1. Dr Amanda Adler, Professor Ken Stein, Dr Ray Armstrong, Dr Jeff Aronson, Professor John Cairns, Mr Matthew Campbell-Hill, Mr Mark Chapman, Professor Daniel Hochhauser, Mrs Anne Joshua Dr Sanjay Kinra, Dr Miriam McCarthy, Professor Ruairidh Milne, Mr Christopher O'Regan, Dr Sanjeev Patel, Professor John Pounsford, Dr Danielle Preedy, Alun Roebuck, Marta Soares and Dr Nicky Welton all declared that they knew of no personal specific pecuniary interest, personal non-specific pecuniary interest, non-personal specific pecuniary interest, non-personal non-specific pecuniary interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of autologous chondrocyte implantation for repairing symptomatic articular cartilage defects of the knee (including a review of TA89).
21. The Chair asked all NICE Staff to declare any relevant interests.

- 21.1. All declared that they knew of no personal specific pecuniary interest, personal non-specific pecuniary interest, non-personal specific pecuniary interest, non-personal non-specific pecuniary interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of autologous chondrocyte implantation for repairing symptomatic articular cartilage defects of the knee (including a review of TA89).
22. The Chair asked all other invited guests assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 22.1. All declared that they knew of no personal specific pecuniary interest, personal non-specific pecuniary interest, non-personal specific pecuniary interest, non-personal non-specific pecuniary interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of autologous chondrocyte implantation for repairing symptomatic articular cartilage defects of the knee (including a review of TA89).
 - 22.2. Professor Martyn Snow declared a personal non specific pecuniary interest as he was the chair of the results committee in the active trial. Professor Martyn Snow also declared a personal specific pecuniary interest as he works in a private practice that uses a device under appraisal.
 - 22.2.1. It was agreed that this declaration would not prevent Professor Martyn Snow from participating in this section of the meeting
 - 22.3. Professor Tim Spalding declared a personal specific pecuniary interest as works in a private practice that uses a device under appraisal.
 - 22.3.1. It was agreed that this declaration would not prevent Professor Tim Spalding from participating in this section of the meeting.
23. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
24. The Committee then discussed the clinical effectiveness, patient perspective and cost effectiveness of autologous chondrocyte implantation for repairing symptomatic articular cartilage defects of the knee (including a review of TA89) on the basis of the evidence before them, and potential equality issues raised in this appraisal. They sought clarification and advice from the experts present. The discussions included:
 - 24.1. The lack of patient expert input
 - 24.2. The clinical effectiveness evidence
 - 24.3. The change in primary outcome of the TIG/ACT trial
 - 24.4. The relevance of evidence from ACI-P and whether the relevant evidence had been captured in the assessment
 - 24.5. Importance of a national registry
 - 24.6. The cost effectiveness evidence
 - 24.7. The new analyses/revisions to the model for ChondroSelect
 - 24.8. The utility of values from SUMMIT
 - 24.9. The appropriateness of potential recommendation for further research
 - 24.10. Request for additional analyses

25. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
26. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
27. The Chair then thanked the experts, company representatives and academic group for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

- 28.
29. The Committee continued to discuss the clinical and cost effectiveness of autologous chondrocyte implantation for repairing symptomatic articular cartilage defects of the knee (including a review of TA89).
30. The Committee agreed to defer a decision on the content of the guidance document until further analysis has been undertaken.

Date, time and venue of the next meeting

31. Thursday 14 May 2015 at Prospero House, 241 Borough High Street, London, SE1 1GA.